(Q43253623)

17 November 2017

title

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients (English)

1 reference

17 November 2017

1 reference

Stephen Sonis

1

1 reference

17 November 2017

Nathaniel Treister

2

1 reference

17 November 2017

Sant Chawla

3

1 reference

17 November 2017

George Demetri

4

1 reference

17 November 2017

Frank Haluska

5

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

17 November 2017

1 reference

17 November 2017

volume

116

1 reference

17 November 2017

issue

1

1 reference

17 November 2017

page(s)

210-215

1 reference

mTOR pathway and mTOR inhibitors as agents for cancer therapy

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

mTOR inhibitors in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

mTOR-targeted therapy of cancer with rapamycin derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.24696

1 reference

7 January 2021

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Clinical practice. Aphthous ulceration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Mucosal disease series. Number VI. Recurrent aphthous stomatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

The pathobiology of mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24696

7 January 2021

Identifiers

DOI

10.1002/CNCR.24696

1 reference

17 November 2017

1 reference